Healthcare
PT Kalbe Farma Tbk.(PTKFY)
Live Price
Offline$8.58
+0.00% today
1Y Change
-50.44%
Window
Jun 23, 2025 โ Jun 11, 2026
- Market Cap
- $39.17T
- Revenue Growth
- +8.3%
- EPS Growth
- +15.3%
- Dividend Yield
- 4.2%
Coverage: 244 bars ยท Jun 23, 2025 โ Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PT Kalbe Farma Tbk. (PTKFY) is a Healthcare stock with a market cap of $39.17T and listed on OTC. The stock last traded around $8.58 and down 50.4% across the available one-year price window (Jun 23, 2025 โ Jun 11, 2026). Baseline metrics include revenue growth of +8.3%, EPS growth of +15.3%, a dividend yield of 4.2%. What stands out right now is revenue +8.3%, EPS +15.3%, free cash flow -30.4% with operating margin 12.3% and ROIC 13.2%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 10.8 and price/sales 1.1. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines PTKFY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+8.3% vs +7.6% peer median
Operating Margin
Below sector median
+12.3% vs +19.4% peer median
P/E
Below sector median
10.8 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 28, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +8.3% and EPS at +15.3%, with operating margin around 12.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 28, 2026 | โ | +0.0% | +0.0% | -10.5% |
2026 Mar 26, 2026 | โ | -15.9% | -4.0% | -12.7% |
2025 Oct 28, 2025 | โ | +0.0% | -9.0% | -1.1% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PTKFY
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PTKFY Max Drawdown
-56.02%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PTKFY and SPY.
Company Overview
PT Kalbe Farma Tbk.
Other OTC
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals, Consumer Health, Nutritionals, and Distribution and Logistic. It offers generic, branded, and licensed drugs, including Brainact, Cefspan, Mycoral, Cernevit, Cravit, Neuralgin, Broadced, Neurotam, Hemapo, and CPG that are distributed to hospitals, pharmacies, and drug stores. The company also provides over-the-counter drugs; energy drinks, ready-to-drink products, supplements, and other preventive products; and nutritional products for infants, toddlers, children, teenagers, adults, pregnant and lactating women, and elders, as well as for consumers with special medical needs. In addition, it offers contract services, including clinical study management, bioavailability/bioequivalence studies, and contract analysis to pharmaceutical companies; and animal health products, as well as operates Mitrasana Clinics, a health care service. Further, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. PT Kalbe Farma Tbk. was incorporated in 1966 and is headquartered in Jakarta, Indonesia.
- Leadership
- Bernadette Ruth Irawati Setiady
- IPO Date
- Aug 13, 2012
- Employees
- 12.8k
- Street Address
- Gedung KALBE
- Mailing
- Jakarta, 10510
- Region
- Jakarta, ID
- Reporting Currency
- USD
- Investor Line
- 62 21 4287 3888
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 10.8
- EV/EBITDA
- 6.9
- Price/Sales
- 1.1
- Price/Book
- 1.6
Growth
- Revenue
- +8.3%
- EPS
- +15.3%
- Free Cash Flow
- -30.4%
Profitability
- Gross Margin
- 38.7%
- Operating Margin
- 12.3%
- Net Margin
- 10.0%
- ROE
- 15.6%
- ROIC
- 13.2%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 3.56
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.